Sunesis Pharmaceuticals (Nasdaq: SNSS) 49.7% HIGHER; announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE